Harvard Bioscience

Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference

Retrieved on: 
Monday, March 11, 2024

HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024.

Key Points: 
  • HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024.
  • Joining him will be Jennifer Cote, the Company’s Chief Financial Officer.
  • Both presentations will be webcast live and can be accessed through the investor relations section of the Harvard Bioscience website: https://investor.harvardbioscience.com/events-and-presentations .
  • The Company’s management will engage in virtual one-on-one meetings with institutional investors in conjunction with both conferences.

Harvard Bioscience Announces Fourth Quarter 2023 Financial Results

Retrieved on: 
Thursday, March 7, 2024

For the fourth quarter of fiscal 2023, the Company reported revenues of $28.2 million compared to $28.4 million in the fourth quarter of fiscal 2022 and included a net reduction of $0.9 million from discontinued products from the fourth quarter of 2022.

Key Points: 
  • For the fourth quarter of fiscal 2023, the Company reported revenues of $28.2 million compared to $28.4 million in the fourth quarter of fiscal 2022 and included a net reduction of $0.9 million from discontinued products from the fourth quarter of 2022.
  • Net loss for the fourth quarter of 2023 was $(1.8) million and included an unfavorable impact of a $(0.3) million unrealized loss on marketable securities.
  • Adjusted EBITDA for the fourth quarter of 2023 was $3.6 million, compared to $3.7 million in the fourth quarter of the prior year.
  • Cash provided by operations for the fourth quarter of 2023 was $4.3 million compared to $2.7 million in the same period last year.

Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Society of Toxicology Meeting

Retrieved on: 
Wednesday, March 6, 2024

Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.

Key Points: 
  • Complementing an already extensive product line, the new innovations provide exciting new opportunities for advancing preclinical and organoid-focused therapy development.
  • The Company’s industry-leading GLP-compliant Ponemah™ preclinical data management platform now includes integrations with the new SoHo™ implantable telemetry solution and the VivaMARS™ high-capacity behavior monitoring system.
  • The integrated platform also opens new opportunities for the use of emerging machine learning-based algorithms to efficiently analyze large data pools.
  • The new Mesh MEA platform is designed for the emerging applications of organoids in research and discovery, safety pharmacology and toxicology.

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

Retrieved on: 
Tuesday, February 27, 2024

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Key Points: 
  • HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
  • Participants who would like to join the call and ask a question must register here .
  • Once registered, you will receive the dial-in numbers and a unique PIN number.
  • Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.

Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors

Retrieved on: 
Thursday, January 11, 2024

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.

Key Points: 
  • Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.
  • The number of directors of Bone Biologics remains at four.
  • “We are delighted that a professional of Rob’s stature has agreed to join our board of directors,” said Jeffrey Frelick, president and chief executive officer of Bone Biologics.
  • Mr. Gagnon currently serves on the Board of Directors at Verastem Oncology and Purple Biotech.

Harvard Bioscience to Present at Benchmark Company’s Discovery One-On-One Investor Conference on December 7, 2023

Retrieved on: 
Monday, November 20, 2023

HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York City.

Key Points: 
  • HOLLISTON, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced it will be presenting at the Benchmark Company 12th Annual Discovery One-on-One Investor Conference to be held Thursday December 7th, 2023 at the New York Athletic Club in New York City.
  • Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer.
  • To schedule a one-on-one meeting with Harvard Bioscience, Inc., you may submit your request online via the link provided upon registration.
  • To register for the conference, please visit https://www.meetmax.com/sched/event_99181/investor_reg_new.html?attendee...

Harvard Bioscience to Present at Southwest IDEAS Investor Conference on November 16, 2023

Retrieved on: 
Thursday, November 9, 2023

HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas.

Key Points: 
  • HOLLISTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present to investors at the Southwest IDEAS Investor Conference on Thursday November 16, 2023 at The Statler in Dallas, Texas.
  • Joining him will be Jennifer Cote, the company’s Chief Financial Officer and Treasurer.
  • A replay of the presentation will be available on the Investor Relations section Harvard Bioscience website shortly after the presentation has concluded.
  • Harvard Bioscience will also host one-on-one meetings with investors on Thursday, November 16.

Harvard Bioscience Announces Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 7, 2023

Adjusted EBITDA for the third quarter of 2023 was $2.2 million, compared to adjusted EBITDA of $1.0 million in the third quarter of 2022.

Key Points: 
  • Adjusted EBITDA for the third quarter of 2023 was $2.2 million, compared to adjusted EBITDA of $1.0 million in the third quarter of 2022.
  • Cash provided by operations for the third quarter of 2023 was $4.4 million compared to $0.6 million in the same period last year.
  • Debt was reduced by $2.8 million, and net debt was reduced by $3.8 million during the third quarter of 2023.
  • Management believes that this non-GAAP financial information is important in comparing current results with prior period results and is useful to investors and financial analysts in assessing the Company’s operating performance.

Harvard Bioscience to Showcase Latest Innovations in Preclinical and Organoid Research at Society for Neuroscience Conference on November 12-15, 2023

Retrieved on: 
Monday, November 6, 2023

HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C.

Key Points: 
  • HOLLISTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that it will be showcasing its latest product innovations at the Society for Neuroscience (SfN) conference from November 12-15, 2023, in Washington, D.C.
  • The latest advancements from the Company’s Data Sciences International (DSI) preclinical business expand the reach of DSI’s industry-leading, GLP-compliant Ponemah™ preclinical data management platform.
  • These advancements include DSI’s new SoHo™ implantable telemetry solution for small animal models and its VivaMARS™ high-capacity behavior monitoring system.
  • Representatives will be present during exhibit hours from Sunday November 12, 2023 through Wednesday November 15, 2023 from 9.30 a.m. to 5.00 p.m. EST.

Harvard Bioscience Schedules Third Quarter 2023 Earnings Conference Call for November 7, 2023 at 8:00 AM ET

Retrieved on: 
Monday, October 30, 2023

HOLLISTON, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2023 before the market opens on November 7, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Key Points: 
  • HOLLISTON, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2023 before the market opens on November 7, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
  • Participants who would like to join the call and ask a question must register here .
  • Once registered, you will receive the dial-in numbers and a unique PIN number.
  • Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.